Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-HepB-Hib-IPV vaccine (BioE)
- Development stage
- Unknown
- Lead developer
- Biological E
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-Hib-IPV (BioE) is a hexavalent combination vaccine developed by Biological E. Limited (BioE). It is designed for pediatric use to provide protection against six major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, Haemophilus influenzae type b (Hib), and poliomyelitis. This formulation is notable for its use of whole-cell pertussis (wP) rather than acellular pertussis (aP), which is often preferred in global health settings for its robust immunogenicity and cost-effectiveness. The vaccine contains diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, recombinant hepatitis B surface antigen (HBsAg), Hib capsular polysaccharide (PRP) conjugated to a carrier protein (typically tetanus toxoid), and inactivated poliovirus (IPV) types 1, 2, and 3. It is intended to simplify the vaccination schedule by reducing the number of injections required for infants.
- Other names
- Hexavalent vaccine (DTwP-HepB-Hib-IPV)Biological E Hexavalent Vaccine
02
Targets
Diphtheria toxinHBsAg (Hepatitis B surface antigen)ETV6 (ETS variant transcription factor 6)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTwP-HepB-Hib-IPV vaccine (BioE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-HepB-Hib-IPV vaccine (BioE).